| Patient | Ella Fitzgerald |
|---|---|
| Date of birth | 1917-04-25 |
| Identifiers | MRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640 |
| Document date | 1987-05-26 |
| Author | Odessa Whitlow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review of the new glucose plan, seen the same day by vascular surgery. [S]
Ms. Fitzgerald returns two weeks after her first visit and is seen by Dr. Okafor-Lane of vascular surgery on the same day. She stopped glipizide, moved glargine 24 units to the morning, and started empagliflozin 10 mg and atorvastatin 80 mg. Her continuous glucose monitor shows glucose between 70 and 180 mg/dL 58% of the time, time below 70 mg/dL 0.5%, with a lowest reading of 68 mg/dL after a long rehearsal, and no reading below 54 mg/dL; there have been no lows after shows. She has no burning or itching with urination and no muscle aches. Calf cramping still stops her after about one and a half blocks, more on the right; she has no rest pain or sores. Her right eye remains blurred; the retina clinic will see her next week. [S]
| Element | Detail |
|---|---|
| Glucose | Time in range 58%; time below 70 mg/dL 0.5%; lowest 68 mg/dL; none below 54 |
| Medicines | Glipizide stopped; glargine 24 units each morning; empagliflozin and atorvastatin 80 mg started, no side effects |
| Claudication | Calf pain after about one and a half blocks; no rest pain |
| Eyes | Retina clinic appointment next week |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Calf cramping on walking; no chest pain, rest pain, or ankle swelling |
| Eyes | Positive | Right-eye blur unchanged |
| Genitourinary | Negative | No burning, itching, or discharge |
| Musculoskeletal | Negative | No muscle aches on the higher statin dose |
| Integumentary | Negative | No foot sores or blisters |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with breakfast and the evening meal | Oral route | 1977-03-01 | active | S |
| Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals | One tablet by mouth twice daily before breakfast and the evening meal | Oral route | 1982-09-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime | 30 units at bedtime | Subcutaneous route | 1984-04-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 24 units under the skin each morning | 24 units each morning, at the same clock time on tour, with written time-zone adjustments | Subcutaneous route | 1987-05-11 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 to 1987-05-11 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-05-11 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery | Oral route | 1987-05-11 | active | S |
| Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose | One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911 | Nasal route | 1987-05-11 | active | S |
| Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg | One tablet by mouth twice daily, with aspirin 81 mg once daily | Oral route | 1987-05-26 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1987-05-26 | Body height | 165 | cm | S |
| 1987-05-26 | Body weight | 83.8 | kg | S |
| 1987-05-26 | Body mass index (BMI) [Ratio] | 30.8 | kg/m2 | S |
| 1987-05-26 | Systolic blood pressure | 124 | mm[Hg] | S |
| 1987-05-26 | Diastolic blood pressure | 70 | mm[Hg] | S |
| 1987-05-26 | Heart rate | 60 | /min | S |
| 1987-05-26 | Respiratory rate | 16 | /min | S |
| 1987-05-26 | Body temperature | 36.5 | Cel | S |
| 1987-05-26 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
Vital signs recorded on 1987-05-26; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 83.8 kg; blood pressure 124/70, pulse 60 |
| Feet | Skin intact; calluses under the second metatarsal heads; hammer toes of the second and third toes; no ulcer; monofilament felt at all sites; feet warm with slow capillary refill on the right |
| Vascular | Femoral pulses present; popliteal and foot pulses absent on the right; foot pulses faint on the left |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | E11.51 | S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic. |
| Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | E11.3311 | S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display. |
| Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | I25.10 | S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months when not at goal or after a change; every six months at goal | Up to date | 8.6% two weeks ago; next at three months |
| Medication safety | Continuous glucose monitor review: time in range and time below range | Every visit | Completed today | Time in range 58%; time below 70 mg/dL 0.5%; none below 54 mg/dL |
| Medication safety | Hypoglycemia events, show-day plan, and glucagon | Every visit | Completed today | No lows after shows; lowest 68 mg/dL after a long rehearsal; glucagon carried; road manager trained |
| Medication safety | Empagliflozin safety: genital infection, volume, and sick-day rules | At the start and every visit | Completed today | No genital symptoms; sick-day rules reviewed for travel days |
| Laboratory | Creatinine, eGFR, and potassium | Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review | Up to date | Creatinine 0.92 mg/dL, eGFR 67, potassium 4.4 mmol/L two weeks ago; next at three months |
| Laboratory | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Due | Atorvastatin raised to 80 mg two weeks ago; lipid panel due 4 to 12 weeks after the change |
| Examination | Foot inspection, protective sensation, and pulses | Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months | Completed today | No ulcer; protective sensation intact; calluses and hammer toes; podiatry appointment within three weeks |
| Imaging | Ankle-brachial and toe-brachial indices | At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms | Up to date | Ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55 at intake; arterial duplex by vascular surgery today |
| Examination | Walking distance and claudication symptoms | Every visit | Completed today | Calf pain after about one and a half blocks; no rest pain |
| Referral | Vascular surgery consultation | Promptly for claudication with an abnormal ankle-brachial index | Completed today | Seen by Dr. Okafor-Lane today |
| Self-management | Supervised exercise therapy | Three times a week for twelve weeks | Ordered | Hospital program starts next week; home walking plan for tour weeks |
| Referral | Retinal examination and visual acuity | With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes | Ordered | Retina clinic next week for the right macular edema |
| Examination | Blood pressure | Every visit | Completed today | 124/70 mmHg, at goal below 130/80 |
| Examination | Weight and BMI | Every visit | Completed today | 83.8 kg |
| Medication safety | Bleeding on rivaroxaban and aspirin | At the start and every visit | Completed today | Starting today; no bleeding history; no anti-inflammatory painkillers |
| Self-management | Access and equity: tour-date scheduling, video visits, large print, drug costs | Every visit | Completed today | Visits set around tour dates; large-print plan given; rivaroxaban cost checked with her Part D plan |
Goal progress:
Guideline basis: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026)
Follow-up: Supervised exercise from next week. Retina clinic next week. Podiatry within three weeks. Annual wellness visit in three weeks. Three-month review with A1c, lipids, and kidney tests. Next scheduled visit 1987-06-15: subsequent annual wellness visit. [S]